Solv, Q4 and EPS Beats
M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to ...
Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...
The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.
Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...
Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Solventum Corporation (SOLV – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results